News | July 08, 2009

First Patient Enrollment in Clinical Trial for Cellular Treatment of Peripheral Artery Disease

July 8, 2009 - Pluristem Therapeutics Inc. said yesterday its first patient enrolled in a phase I clinical trial that will evaluate the safety of the company’s allogeneic, placental-derived, adherent stromal cell product, termed PLX-PAD. The product is for use in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Up to 15 adults with the disease will be included in the trial, which is being conducted at the Franziskus-Krankenhaus Hospital and Charité - Universitätsmedizin Hospital in Berlin.

The Paul Ehrlich Institute recently approved the company to begin clinical trials with PLX-PAD.

PLX-PAD is a cellular therapeutic product derived from the placenta and is a ubiquitous source of adult stromal cells easily obtained without harm to the mother or baby.

For more information: www.pluristem.com

Related Content

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).

Technology | Peripheral Artery Disease (PAD) | April 15, 2019

FDA Clears Intact Vascular’s Tack Endovascular System

April 15, 2019 – Intact Vascular Inc. received U.S.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor

New Peripheral Stent Technology

In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor

Safety of Paclitaxel-eluting Stents and Balloons Called Into Question

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003

News | Peripheral Artery Disease (PAD) | January 25, 2019

Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia

January 25, 2019 — Profusa announced promising...

News | Peripheral Artery Disease (PAD) | January 23, 2019

BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal

A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...

News | Peripheral Artery Disease (PAD) | January 17, 2019

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents

The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...

News | Peripheral Artery Disease (PAD) | December 19, 2018

New Appropriate Use Criteria Released for Peripheral Artery Interventions

A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...

News | Peripheral Artery Disease (PAD) | December 04, 2018

Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries

New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...

News | Peripheral Artery Disease (PAD) | November 09, 2018

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

November 9, 2018 — VentureMed Group Inc.

News | Peripheral Artery Disease (PAD) | November 07, 2018

Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee

The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...